Respiratory syncytial virus infections: recent prospects for control.
Respiratory syncytial virus (RSV) infections remain a significant public health problem throughout the world, although recently developed and clinically approved anti-RSV antibodies administered prophylactically to at-risk populations appear to have significantly affected the disease development. Much effort has been expended to develop effective anti-RSV therapies, using both in vitro assay systems and mouse, cotton rat, and primate models, with several products now in various stages of clinical study. Several products are also being considered for the treatment of clinical symptoms of RSV. In this review, updates on the status of the approved anti-RSV antibodies, ribavirin, and recent results of studies with potential new anti-RSV compounds are summarized and discussed.
Sidwell
Robert W
RW
Institute for Antiviral Research, Utah State University, 5600 Old Main Hill, Logan, UT 84322-5600, United States. Rsidwell@cc.usu.edu
Barnard
Dale L
DL
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000914:Antibodies, Viral / Q000627:therapeutic use*; D000998:Antiviral Agents / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D004791:Enzyme Inhibitors / Q000737:chemistry / Q000494:pharmacology; D006801:Humans; D051379:Mice; D018357:Respiratory Syncytial Virus Infections / Q000188:drug therapy / Q000276:immunology / Q000517:prevention & control*; D018113:Respiratory Syncytial Virus, Human / Q000187:drug effects*; D014764:Viral Proteins / Q000009:adverse effects
D000911:Antibodies, Monoclonal; D000914:Antibodies, Viral; D000998:Antiviral Agents; D004791:Enzyme Inhibitors; D014764:Viral Proteins